药物遗传学：从实验室到字节——指南更新。
Pharmacogenetics: from bench to byte--an update of guidelines.
机构信息
Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.
出版信息
Clin Pharmacol Ther. 2011 May;89(5):662-73. doi: 10.1038/clpt.2011.34. Epub 2011 Mar 16.
Currently, there are very few guidelines linking the results of pharmacogenetic tests to specific therapeutic recommendations. Therefore, the Royal Dutch Association for the Advancement of Pharmacy established the Pharmacogenetics Working Group with the objective of developing pharmacogenetics-based therapeutic (dose) recommendations. After systematic review of the literature, recommendations were developed for 53 drugs associated with genes coding for CYP2D6, CYP2C19, CYP2C9, thiopurine-S-methyltransferase (TPMT), dihydropyrimidine dehydrogenase (DPD), vitamin K epoxide reductase (VKORC1), uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1), HLA-B44, HLA-B*5701, CYP3A5, and factor V Leiden (FVL).
目前，将药物遗传学检测结果与具体治疗建议联系起来的指南非常少。因此，荷兰皇家药剂师协会成立了药物遗传学工作组，目的是制定基于药物遗传学的治疗（剂量）建议。在对文献进行系统回顾后，为与 CYP2D6、CYP2C19、CYP2C9、硫嘌呤-S-甲基转移酶（TPMT）、二氢嘧啶脱氢酶（DPD）、维生素 K 环氧化物还原酶（VKORC1）、尿苷二磷酸葡萄糖醛酸基转移酶 1A1（UGT1A1）、HLA-B44、HLA-B*5701、CYP3A5 和因子 V Leiden（FVL）相关的 53 种药物制定了治疗建议。
Zotero 插件